Disposition kinetics of ropivacaine in humans. 1989

A Lee, and D Fagan, and M Lamont, and G T Tucker, and M Halldin, and D B Scott
Department of Anaesthetics, Royal Infirmary, Edinburgh, Scotland.

The pharmacokinetic characteristics of a new local anesthetic drug, ropivacaine, were determined after intravenous infusion of 50 mg of the hydrochloride salt into six healthy male volunteers. Results showed that the disposition of ropivacaine can be described by a biexponential function. Its blood clearance (0.72 +/- 0.16 L/min) is intermediate between that of mepivacaine and bupivacaine. Plasma binding averaged 94% +/- 1% and the volume of distribution at steady state based on blood drug concentration was 59 +/- 7 L. The terminal elimination half-life was 111 +/- 62 min.

UI MeSH Term Description Entries
D008297 Male Males
D008619 Mepivacaine A local anesthetic that is chemically related to BUPIVACAINE but pharmacologically related to LIDOCAINE. It is indicated for infiltration, nerve block, and epidural anesthesia. Mepivacaine is effective topically only in large doses and therefore should not be used by this route. (From AMA Drug Evaluations, 1994, p168) Carbocaine,Carbocaïne,Isocaine,Isogaine,Meaverin,Mecain,Mepihexal,Mepivacain-Injektopas,Mepivacaina Braun,Mepivacaine Hydrochloride,Mepivacaine Monohydrochloride,Mepivastesin,Polocaine,Scandicain,Scandicaine,Scandinibsa,Scandonest,Mepivacain Injektopas
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D002045 Bupivacaine A widely used local anesthetic agent. 1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide,Bupivacain Janapharm,Bupivacain-RPR,Bupivacaina Braun,Bupivacaine Anhydrous,Bupivacaine Carbonate,Bupivacaine Hydrochloride,Bupivacaine Monohydrochloride, Monohydrate,Buvacaina,Carbostesin,Dolanaest,Marcain,Marcaine,Sensorcaine,Svedocain Sin Vasoconstr,Bupivacain RPR
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077212 Ropivacaine An anilide used as a long-acting local anesthetic. It has a differential blocking effect on sensory and motor neurons. 1-Propyl-2',6'-pipecoloxylidide,AL 381,AL-381,LEA 103,LEA-103,Naropeine,Naropin,Ropivacaine Hydrochloride,Ropivacaine Monohydrochloride,Ropivacaine Monohydrochloride, (S)-isomer,1 Propyl 2',6' pipecoloxylidide,AL381,LEA103
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000577 Amides Organic compounds containing the -CO-NH2 radical. Amides are derived from acids by replacement of -OH by -NH2 or from ammonia by the replacement of H by an acyl group. (From Grant & Hackh's Chemical Dictionary, 5th ed) Amide
D012995 Solubility The ability of a substance to be dissolved, i.e. to form a solution with another substance. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed) Solubilities

Related Publications

A Lee, and D Fagan, and M Lamont, and G T Tucker, and M Halldin, and D B Scott
February 1985, Paraplegia,
A Lee, and D Fagan, and M Lamont, and G T Tucker, and M Halldin, and D B Scott
November 1982, Journal of pharmaceutical sciences,
A Lee, and D Fagan, and M Lamont, and G T Tucker, and M Halldin, and D B Scott
October 2006, Journal of clinical pharmacology,
A Lee, and D Fagan, and M Lamont, and G T Tucker, and M Halldin, and D B Scott
January 1983, European journal of clinical pharmacology,
A Lee, and D Fagan, and M Lamont, and G T Tucker, and M Halldin, and D B Scott
October 2019, Environmental pollution (Barking, Essex : 1987),
A Lee, and D Fagan, and M Lamont, and G T Tucker, and M Halldin, and D B Scott
November 1987, Clinical pharmacology and therapeutics,
A Lee, and D Fagan, and M Lamont, and G T Tucker, and M Halldin, and D B Scott
April 1983, The Journal of the American Paraplegia Society,
A Lee, and D Fagan, and M Lamont, and G T Tucker, and M Halldin, and D B Scott
January 1993, Toxicology and applied pharmacology,
A Lee, and D Fagan, and M Lamont, and G T Tucker, and M Halldin, and D B Scott
June 2003, Clinical chemistry,
A Lee, and D Fagan, and M Lamont, and G T Tucker, and M Halldin, and D B Scott
October 1983, British journal of clinical pharmacology,
Copied contents to your clipboard!